MedTrace Logo

Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

NCT01396434 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3006

Last updated 2017-01-30

Study results available
· View outcomes & findings →

Summary

Prevenar 13 is safe for administration to Filipinos.

Conditions

  • Pneumococcal Disease

Interventions

BIOLOGICAL

Prevenar 13

Prevenar 13 vaccine as prescribed by the physician based on approved product indication

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
6 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01396434 on ClinicalTrials.gov